Discover the groundbreaking potential of HER2-CD3-Fc bispecific antibody-encoding mRNA delivered by lipid nanoparticles in suppressing HER2-positive tumor growth. Our latest publication highlights the robust expression and potent T cell cytotoxicity induced by HER2-CD3-Fc mRNA-LNPs, demonstrating a promising therapeutic approach for treating HER2-positive cancer. Learn more about this innovative therapy by reading our full study here: https://hubs.li/Q02KrwZJ0
ProMab Biotechnologies, Inc.’s Post
More Relevant Posts
-
The “abscopal effect” is defined as regression of distant nontreated sites following primary irradiation of a specific site. The “adscopal effect," as defined by Anthony Conley et al. in a just-published editorial from the journal, Molecular Cancer Therapeutics, refers to systemic, immune-mediated shrinkage of untreated tumors after local injection with the oncolytic adenovirus, AdAPT-001, which expresses a TGF-β trap at high levels. Read here: bit.ly/3vZx0B7
To view or add a comment, sign in
-
“By changing the architecture of the ECM to allow for better drug penetration, the LOX inhibitor enables the chemotherapy to stress the tumor into producing more reactive oxygen species (ROS) more effectively. At high enough levels, ROS creates DNA damage that can lead to cell death. Importantly, inhibiting LOX also blocks focal adhesion kinase (FAK) signaling, which would otherwise promote DNA repair. Taken together, these effects can overcome chemotherapy resistance. Further, these effects were found in different types of models, including triple-negative breast cancer cell lines, in vivo models and organoid models created from patient-derived xenografts.” #cancer #breastcancer #cancerresearch #triplenegativebreastcancer #DNArepair #protemics #DNArepair #tumor
To view or add a comment, sign in
-
MSAT Scientist I Personalized Medicine I Ai/ML| hiPSCs stem cells | Analytics & QC | cGMP | Cell & Gene Therapy | CAR-T ♋I CAR-T | ImmunoTherapy | Gene editing CRISPR🧬✂️ #CAR-T🔬🦠🩸🫁🫀|
A new allogeneic CAR-T cell platform that maintains T-cell stemness, has a more favorable cytokine profile, and demonstrates durable efficacy compared to CAR-T cells derived from adult peripheral blood mononuclear cells (PBMCs). Celularity's data, published in the Journal for ImmunoTherapy of Cancer, highlights the advantages of using placental circulating T cells for CAR-T therapy. The study found that placental T cells exhibit greater persistence, resistance to exhaustion, and efficacy compared to peripheral blood mononuclear cells. https://lnkd.in/gdMPrPaR
To view or add a comment, sign in
-
Resurgence of Smart 🎯 Chemo is on the rise 🚀 , led by Antibody Drug Conjugates that precisely deliver cytotoxic drugs 💊 to tumor cells whilst sparing normal cells the toxicity ☢ of chemotherapeutic agents. Here is a good introduction to ADCs. https://lnkd.in/e69-_g_g #chemotherapy #adc #cancer #cancerresearch #cancertreatment #oncology #oncologyresearch #precisiononcology #precisionmedicine
Rise of Antibody-Drug Conjugates: The Present and Future
ascopubs.org
To view or add a comment, sign in
-
Learn how to leverage microplate reader technology to streamline and enhance your organoid-based cancer research. This NEW #webinar, presented by Krystal Courtney Belmonte, Ph.D. and Angeline Lim, Ph.D. showcases innovative techniques for identifying and assessing drug candidates using patient-derived colorectal #cancer #organoids. https://lnkd.in/e9p2Rayd
Accelerating Cancer Research: Microplate Reader-Based Viability Analysis for Rapid Drug Candidate Identification in Patient-Derived Organoids
moleculardevices.com
To view or add a comment, sign in
-
Please join on discussion of bispecific antibody discovery. How structure and function drives novel MOA
NEW WEBINAR! Endpoints: Considerations for Hit to Lead Selection of a Bispecific Antibody in Oncology Tuesday, July 16, 2024 8:00 am PT, 11:00 am ET, 17:00 CET In this GEN webinar,Mark Chiu, PhD, will present a process for selecting an EGFR x cMET bispecific antibody to treat patients with EGFR inhibitor-resistant non-small lung cancer. Register now to join us for this free webinar sponsored by Cell Signaling Technology (CST): https://ow.ly/xmLa50SqsXF #Cancer #DrugDiscovery #TranslationalMedicine
To view or add a comment, sign in
-
🌟 Highly Cited Paper Spotlight! 🌟 Recent Advancements in Mitochondria-Targeted Nanoparticle Drug Delivery for Cancer Therapy By Jiangsheng Xu et al. This paper discusses recent advancements in using nanoparticles to deliver drugs that target mitochondria in cancer therapy, highlighting how these technologies enhance the effectiveness of treatments like photodynamic, photothermal, and chemotherapy while minimizing damage to healthy tissue. It also explores the potential for developing more specific mitochondria-targeting ligands and the importance of targeting mitochondria in improving the treatment of various diseases associated with mitochondrial dysfunction. Access the full paper at: mdpi.com/1512230
To view or add a comment, sign in
-
Antibody-drug conjugate: the “biological missile” for targeted cancer therapy. Herein, researchers conducted a review of the history and general mechanism of action of Antibody–drug conjugates (ADCs), and then briefly discussed the molecular aspects of key components of ADCs and the mechanisms by which these key factors influence the activities of ADCs. https://hubs.ly/Q02vrrjz0
To view or add a comment, sign in
-
Managing Director, Strategy & Solutions, at Amazon Web Services (AWS) | Driving healthcare transformation via strategic, science-backed innovation
🧬🔬 Dr. Ping Mu and his team unveil pivotal findings in prostate cancer research, identifying genes ZNF397 and TET2 as key factors in therapy resistance due to lineage plasticity. Published in Cancer Discovery, their study reveals how these genes help cancer cells evade standard treatments, presenting a new target for innovative therapies. These insights deepen our understanding of drug resistance mechanisms and pave the way for drugs that could reverse resistance in advanced prostate cancer cases. #CancerResearch #ProstateCancer #TherapyResistance #MedicalInnovation Read more: https://lnkd.in/d5fRVgJW
To view or add a comment, sign in
-
I am thrilled to share that the second review paper, titled “Enhancing Therapeutic Efficacy in Cancer Treatment: Integrating Nanomedicine with Autophagy Inhibition Strategies,” has just been published in ACS Omega! This review highlights the dual role of autophagy in cancer, where it can both suppress and promote tumor growth depending on the stage. By focusing on the inhibition of autophagy, the article explores innovative strategies to enhance cancer treatment, offering a comprehensive overview of recent advancements in the field. Read it here: https://lnkd.in/dqEuNu5P
To view or add a comment, sign in
1,481 followers